Abstract
Background:
Atopic comorbidities are common in chronic spontaneous urticaria (CSU), yet their impact on clinical presentation and omalizumab response remains poorly defined.
Objective:
To compare clinical profiles and omalizumab treatment outcomes in CSU patients with atopic dermatitis (AD) and other atopic comorbidities (OACs).
Methods:
This single-center retrospective study included 381 CSU patients treated with ≥3 doses of omalizumab (300 mg/4 weeks) and followed ≥6 months (January 2023–March 2025). Based on the presence or history of atopic comorbidities, patients were stratified into 3 groups: CSU with AD (CSU-AD, n = 76), CSU with OACs (CSU-OACs, n = 93), and CSU with no atopic comorbidities (CSU-NA, n = 212). Clinical features, treatment response (efficacy, speed, and adverse events), and—among 12-month completers—dose reduction/discontinuation and drug survival rates were analyzed.
Results:
Of all enrolled patients, 44.4% had comorbid allergic diseases. CSU-OACs patients had earlier onset (P = 0.033) and higher angioedema prevalence (P = 0.042); CSU-AD showed higher baseline UAS7 (P = 0.031). Overall omalizumab response rates did not differ significantly among the 3 groups (P = 0.115), but a significantly higher portion of faster-response speed was observed in CSU-OAC (P = 0.019). Adverse events were significantly higher in CSU-OACs (P = 0.004), especially injection-site reactions (P = 0.033) and systemic effects (eg, headache and fatigue; P = 0.025). Drug survival was significantly higher in the CSU-OAC vs. CSU-NA group (P = 0.007).
Conclusion:
CSU-AD differs only in higher baseline activity, otherwise resembling CSU-NA in treatment response and drug survival. CSU-OACs exhibit not only distinct features such as earlier onset, higher angioedema risk, faster response, and higher drug survival but also more adverse events, indicating that CSU-OAC requires individualized management. Larger multicenter studies are needed to further define the impact of AD and OACs in CSU.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
